Session date: May 24, 2023
This session will focus on the pathobiology, approach to treatment, the role of cough as a potential biomarker of disease activity/progression and current landscape of recent on ongoing research on cough in patients with pulmonary fibrosis.
This session will focus on the pathobiology, approach to treatment, the role of cough as a potential biomarker of disease activity/progression and current landscape of recent on ongoing research on cough in patients with pulmonary fibrosis.
• Describe the mechanisms of cough and treat cough in patients with pulmonary fibrosis
• Refer patients with pulmonary fibrosis to ongoing clinical trials
• Measure cough in a standardized manner
Surinder Birring, MD
Marlies Wijsenbeek, MD, PhD
Toby Maher, Md, MSc,PhD, FRCP
Steven Nathan, MD
Understanding the Pathobiology of Cough in Patients with Pulmonary Fibrosis
Approach to Patient with Pulmonary Fibrosis and Cough, What Can We Learn from the Chronic Cough Field?
Cough as a Prognostic Biomarker, Should We Be Formally Measuring in Clinical Practice?
Cough in Pulmonary Fibrosis Clinical Trials: Nothing to Sneeze At